Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Invitrogen™ Daclizumab Chimeric Recombinant Rabbit Monoclonal Antibody (Daclizumab)
GREENER_CHOICE

Catalog No. PIMA547834
Change view
Click to view available options
Quantity:
200 μg
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
PIMA547834 200 μg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Catalog No. PIMA547834 Supplier Invitrogen™ Supplier No. MA547834
Add to Cart
Add to Cart

Rabbit Recombinant Monoclonal Antibody

Specificity: Binds to p55 chain of IL2R on human T cells, Tac antigen, which is expressed on T cells activated by mitogens, soluble antigens, and alloantigens but not on resting T cells, thymocytes, B cells, monocytes, activated B cells, leukemic T cell blasts from patients with acute lymphoblastic leukemia, and long-term T cell lines.

Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody. On 22 April 2008, Roche Registration Limited chose to voluntarily withdraw the marketing authorization for their product Zenapax (daclizumab), as indicated for the prophylaxis of acute organ rejection in de novo allogeneic renal transplantation and used concomitantly with an immunosuppressive regimen like cyclosporine and corticosteroids in patients who are not immunized, for commercial reasons and confirmed that this decision was not related to any safety concerns associated with the use of Zenapax (daclizumab) 2. Regardless of the withdrawal of Zenapax, Biogen and Abbvie's Zinbryta (daclizumab), as indicated for the treatment of adult patients with relapsing forms of multiple sclerosis, was approved for use by the FDA in 2016.
TRUSTED_SUSTAINABILITY

Specifications

Antigen Daclizumab Chimeric
Applications Flow Cytometry, Inhibition Assays
Classification Recombinant Monoclonal
Clone Daclizumab
Concentration 1 mg/mL
Conjugate Unconjugated
Formulation PBS with 0.02% ProClin 300
Gene HLA-DQB1
Gene Accession No. P01911, P01920, P04440
Gene Alias BIIB019; DAC HYP
Host Species Rabbit
Immunogen Cultured T-cells derived from a patient with Mycosis fungoides.
Purification Method Protein A
Quantity 200 μg
Regulatory Status RUO
Primary or Secondary Primary
Gene ID (Entrez) 3115, 3119, 3123
Target Species Cynomolgus Monkey, Human, Rhesus Macaque
Content And Storage Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Product Type Antibody
Form Liquid
Isotype IgG κ
Show More Show Less
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.